The Changing Landscape Of Relapsed And/or Refractory Multiple ...
Access Blocked Your IP has been blocked due to suspicious activity. If you believe this is an error, please contact support and include the debug information below in your message.
Debug Information
Server: cache-sin-wsat1880053-SIN
Client: 103.110.85.167
Debug: c8446f59cca2149cb5f56ced4b448c8d / t12d280700_b75078996b15_6b16546de802
Từ khóa » Cc-92480-mm-003
-
A Study To Determine The Recommended Dose And ... - Clinical Trials
-
A Safety, PK And Efficacy Study Of CC-92480 Monotherapy And In ...
-
Phase I Trial Supports CC-92480 For Heavily Pretreated Myeloma
-
CELMoD CC-92480/Dexamethasone Combo Shows Early Activity In ...
-
Mezigdomide - Bristol-Myers Squibb - AdisInsight - Springer
-
Novel Non-Immunologic Agents For Relapsed And Refractory ... - NCBI
-
Promising Therapeutic Approaches For Relapsed/refractory Multiple ...
-
Aiding Early Clinical Drug Development By Elucidation Of The ...
-
Treatment Options For Patients With Heavily Pretreated Relapsed ...
-
[PDF] Developing Next Generation Immunomodulatory Drugs And Their ...
-
CC-92480 Shows Encouraging Efficacy In First-in-Human Study For ...
-
Bristol Myers Squibb To Highlight More Than 80 Abstracts At ASH ...
-
Multiple Myeloma Clinical Trials In Georgia